The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
Related stories
It’s the strangest job market the U.S. has ever seen. The low-hire, low-fire economy turns 3 years old.
DoorDash to acquire Instacart for $17bn
You can’t rely on the S&P 500 as much as you may think
Christine Lagarde departs at a moment of peril
The never-ending absurdity of global oil markets
The Fed held off on a rate hike. Today’s GDP and inflation reports could make waiting harder.